These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 23797470

  • 1. Moxifloxacin in complicated skin and skin structure infections (cSSSIs): A prospective, international, non-interventional, observational study.
    Bogner JR, Kutaiman A, Esguerra-Alcalen M, Heldner S, Arvis P.
    Adv Ther; 2013 Jun; 30(6):630-43. PubMed ID: 23797470
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of sequential intravenous/oral moxifloxacin vs intravenous/oral amoxicillin/clavulanate for complicated skin and skin structure infections.
    Vick-Fragoso R, Hernández-Oliva G, Cruz-Alcázar J, Amábile-Cuevas CF, Arvis P, Reimnitz P, Bogner JR, STIC Study Group.
    Infection; 2009 Oct; 37(5):407-17. PubMed ID: 19768381
    [Abstract] [Full Text] [Related]

  • 3. A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections.
    Gyssens IC, Dryden M, Kujath P, Nathwani D, Schaper N, Hampel B, Reimnitz P, Alder J, Arvis P.
    J Antimicrob Chemother; 2011 Nov; 66(11):2632-42. PubMed ID: 21896561
    [Abstract] [Full Text] [Related]

  • 4. Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate.
    Lipsky BA, Giordano P, Choudhri S, Song J.
    J Antimicrob Chemother; 2007 Aug; 60(2):370-6. PubMed ID: 17553812
    [Abstract] [Full Text] [Related]

  • 5. Characterisation of patients receiving moxifloxacin for acute bacterial rhinosinusitis in clinical practice: results from an international, observational cohort study.
    Mösges R, Desrosiers M, Arvis P, Heldner S.
    PLoS One; 2013 Aug; 8(4):e61927. PubMed ID: 23626752
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics and penetration of moxifloxacin into infected diabetic foot tissue in a large diabetic patient cohort.
    Majcher-Peszynska J, Sass M, Schipper S, Czaika V, Gussmann A, Lobmann R, Mundkowski RG, Luebbert C, Kujath P, Ruf BR, Koch H, Schareck W, Klar E, Drewelow B, Moxifloxacin-DFI Study Group.
    Eur J Clin Pharmacol; 2011 Feb; 67(2):135-42. PubMed ID: 20871984
    [Abstract] [Full Text] [Related]

  • 7. Sequential intravenous/oral moxifloxacin monotherapy for complicated skin and skin structure infections: a meta-analysis of randomised controlled trials.
    Chen F, Zheng N, Wang Y, Wen JL, Tu WF, Du YQ, Lin JM.
    Int J Clin Pract; 2013 Sep; 67(9):834-42. PubMed ID: 23952463
    [Abstract] [Full Text] [Related]

  • 8. Prospective, randomized, study of ampicillin-sulbactam versus moxifloxacin monotherapy for the treatment of community-acquired complicated intra-abdominal infections.
    Chen CW, Ming CC, Ma CJ, Shan YS, Yeh YS, Wang JY.
    Surg Infect (Larchmt); 2013 Aug; 14(4):389-96. PubMed ID: 23859673
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and tolerability of moxifloxacin in patients with respiratory tract infections treated in general practice: Results of a post-marketing surveillance study.
    Chen W, Wu C, Li Z, Bai C.
    Clin Drug Investig; 2006 Aug; 26(9):501-9. PubMed ID: 17163283
    [Abstract] [Full Text] [Related]

  • 10. Sequential intravenous/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection.
    Giordano P, Song J, Pertel P, Herrington J, Kowalsky S.
    Int J Antimicrob Agents; 2005 Nov; 26(5):357-65. PubMed ID: 16229991
    [Abstract] [Full Text] [Related]

  • 11. Real-life treatment of acute exacerbations of chronic bronchitis with moxifloxacin or macrolides: a comparative post-marketing surveillance study in general practice.
    Schaberg T, Möller M, File T, Stauch K, Landen H.
    Clin Drug Investig; 2006 Nov; 26(12):733-44. PubMed ID: 17274680
    [Abstract] [Full Text] [Related]

  • 12. [Selection of empirical antibiotic therapy in skin infections with complications].
    Chosidow O.
    Med Mal Infect; 2011 Jan; 41(1 Suppl 1):H4-5. PubMed ID: 21335252
    [No Abstract] [Full Text] [Related]

  • 13. A post hoc subgroup analysis of meropenem versus imipenem/cilastatin in a multicenter, double-blind, randomized study of complicated skin and skin-structure infections in patients with diabetes mellitus.
    Embil JM, Soto NE, Melnick DA.
    Clin Ther; 2006 Aug; 28(8):1164-1174. PubMed ID: 16982293
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Community Acquired Pneumonia Study Group.
    Patel T, Pearl J, Williams J, Haverstock D, Church D.
    Respir Med; 2000 Feb; 94(2):97-105. PubMed ID: 10714413
    [Abstract] [Full Text] [Related]

  • 15. The role of topical moxifloxacin, a new antibacterial in Europe, in the treatment of bacterial conjunctivitis.
    Benitez-Del-Castillo J, Verboven Y, Stroman D, Kodjikian L.
    Clin Drug Investig; 2011 Feb; 31(8):543-557. PubMed ID: 21604820
    [Abstract] [Full Text] [Related]

  • 16. [A severe cutaneous anthrax case complicated with sepsis in Bursa, Turkey].
    Durmuş G, Yeşilyurt M, Karagöz A, Demir C, Eren N, Kılıç S.
    Mikrobiyol Bul; 2013 Jul; 47(3):529-37. PubMed ID: 23971931
    [Abstract] [Full Text] [Related]

  • 17. Comparative efficacy and safety of moxifloxacin and clindamycin in the treatment of odontogenic abscesses and inflammatory infiltrates: a phase II, double-blind, randomized trial.
    Cachovan G, Böger RH, Giersdorf I, Hallier O, Streichert T, Haddad M, Platzer U, Schön G, Wegscheider K, Sobottka I.
    Antimicrob Agents Chemother; 2011 Mar; 55(3):1142-7. PubMed ID: 21173173
    [Abstract] [Full Text] [Related]

  • 18. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
    Anzueto A, Niederman MS, Pearle J, Restrepo MI, Heyder A, Choudhri SH, Community-Acquired Pneumonia Recovery in the Elderly Study Group.
    Clin Infect Dis; 2006 Jan 01; 42(1):73-81. PubMed ID: 16323095
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study.
    Schaper NC, Dryden M, Kujath P, Nathwani D, Arvis P, Reimnitz P, Alder J, Gyssens IC.
    Infection; 2013 Feb 01; 41(1):175-86. PubMed ID: 23180507
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis: a prospective, multicenter, observational study (AVANTI).
    Chuchalin A, Zakharova M, Dokic D, Tokić M, Marschall HP, Petri T.
    BMC Pulm Med; 2013 Jan 23; 13():5. PubMed ID: 23343427
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.